Document is current
Any future updates will be listed below
-
Authors
Distler, Jörg H. W. https://orcid.org/0000-0001-7408-9333
Kuwana, Masataka https://orcid.org/0000-0001-8352-6136
Assassi, Shervin https://orcid.org/0000-0002-8059-9978
Denton, Christopher P. https://orcid.org/0000-0003-3975-8938
- License Information
-
More Information
Article History
Accepted: 1 August 2025
First Online: 8 September 2025
Competing interests
: J.H.W.D. has consultancy relationships with Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Callidatas, Calluna, Galapagos, GSK, Johnson&Johnson, Kyverna, MSD, Novartis, Prolium, Quell Therapeutics and UCB, has research funding from Anamar, ARXX, BMS, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, Exo Therapeutics, Galapagos, GSK, Incyte, Inventiva, Kiniksa, Kyverna, Lassen Therapeutics, Mestag, Sanofi-Aventis, SpicaTx, RedX, UCB and ZenasBio, and is CEO of 4D Science and scientific lead of FibroCure. M.K. has received consultancy fees, speaking fees, and research grants from AbbVie, Argenx, Asahi Kasei, AstraZeneca, Boehringer Ingelheim, Chugai, GlaxoSmithKline, Janssen, Kissei, MBL, Mitsubishi Tanabe, Mochida, Novartis and Ono Pharmaceuticals. S.A. reports grants paid to his institution from Boehringer Ingelheim, the Scleroderma Research Foundation, Janssen and aTyr, as well as consultancy fees from AbbVie, AstraZeneca, aTyr, Boehringer Ingelheim, CSL Behring, Merck, Mitsubishi Tanabe, Takeda, and TeneoFour. C.P.D. has consultancy relationships with GlaxoSmithKline, Johnson&Johnson, Bayer, Sanofi, Boehringer Ingelheim, Roche, CSL Behring, Corbus, Acceleron, Horizon, Arxx, Lilly, Novartis, Certa, Mitsubishi, Quell and research grant funding from AbbVie, Arxx, Horizon, GlaxoSmithKline, CSL Behring and Servier.
